RxDoctor Payments Data

Mark Rorick, MD

Neurology · Chardon, OHNPI 1790788727

Payments from drug & device makers

$4,212in general payments, 2019–2025

Across 392 payments — averaging $10.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Supernus Pharmaceuticals, Inc.$542
  • UCB, Inc.$540
  • Novartis$444
  • Teva Pharmaceuticals USA, Inc.$325
  • EMD Serono, Inc.$240
  • plus $662 from 12 others

What the payments were for

  • Food & beverage$4,11198%
  • Education$1022%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,212 in reported general payments places this provider in the 60th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$61,593
Medicare patients
361
Services billed
478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BetaseronInterferon Beta-1b13$124,251
TecfideraDimethyl Fumarate12$113,225
BriviactBrivaracetam52$83,992
Nurtec OdtRimegepant Sulfate39$65,006
Keppra XrLevetiracetam17$17,641
Aimovig AutoinjectorErenumab-Aooe18$13,030
Memantine Hcl257$9,904
Emgality PenGalcanezumab-Gnlm14$9,769
Levetiracetam327$9,037
Lacosamide100$7,185
DilantinPhenytoin Sodium Extended17$5,085
Carbamazepine ErCarbamazepine20$3,135
Gabapentin205$3,043
Clorazepate Dipotassium11$2,770
Carbamazepine55$2,646

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$114$113,22512 claims
UCB, Inc.Briviact$540$83,99252 claims
PfizerNurtec Odt, Dilantin$18$70,09256 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 702 neurology providers in Ohio.

Other neurology in Chardon

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →